Hemolysin antigens and vaccine embodiments for bacterial infection
AssigneeBaylor College of Medicine
InventorsYikun Xing, Anthony Maresso, Justin R. Clark
Life of this patent
Estimating the term…
Loading patent…
AssigneeBaylor College of Medicine
InventorsYikun Xing, Anthony Maresso, Justin R. Clark
Estimating the term…
Embodiments of the disclosure include methods of treating, preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of an infection (including pathogenic) in an individual infected with a bacteria from the Gammaproteobacteria Class. In specific embodiments, the methods comprise the step of administering to the individual an effective amount of an immunogenic composition comprising a non-acylated/inactive form alphahemolysin (HlyA) and/or a non-acylated/inactive form, or functional fragment(s) of either. In specific embodiments, the individual is also provided a composition comprising SinH or a functional fragment thereof.
A method of treating, preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of an infection in an individual of a bacteria from the Gammaproteobacteria Class, comprising the step of administering to the individual an effective amount of a composition comprising a non-acylated/inactive form alpha-hemolysin (HlyA) and/or a non-acylated/inactive form or functional fragment thereof.
A method of vaccinating an individual for a pathogenic infection of a bacteria from the Gammaproteobacteria Class, comprising the step of administering to the individual an effective amount of a composition comprising a non-acylated/inactive form of alpha-hemolysin (HlyA) and/or a non-acylated/inactive form or functional fragment thereof.
A method of preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of the systemic spread of bacteria to one or more major organ systems of an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof or a functional fragment thereof.
A method of reducing the bacterial burden of an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof
A method of preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of bacteremia in an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof.
A method of preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of a urinary tract infection in an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof.
A method of preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of colonization of bacteria from the Gammaproteobacteria Class in an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof.
A method of preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of sepsis in an individual, comprising the step of administering to the individual an effective amount of a composition comprising the non-acylated/inactive form of HlyA and/or a non-acylated/inactive form or functional fragment thereof.
The method of any one of the preceding claims, further comprising the step of administering to the individual an effective amount of a composition comprising SinH or a functional fragment thereof.
The method of any one of the preceding claims, wherein the bacteria is drug-resistant.
The method of any one of the preceding claims, wherein the bacteria is multidrug-resistant.
The method of any one of the preceding claims, wherein the bacteria is E. coli and the E. coli is ST73, ST95, or ST131.
The method of any one of the preceding claims, wherein the bacteria is extraintestinal pathogenic Escherichia coli (ExPEC).
The method of any one of the preceding claims, wherein the functional fragment of SinH comprises extracellular domain 1, domain 2, and/or domain 3.
The method of any one of the preceding claims, wherein the infection is local.
The method of any one of the preceding claims, wherein the infection is systemic.
The method of any one of the preceding claims, wherein the individual is immunocompromised.
The method of any one of the preceding claims, wherein the individual is an infant, child, adolescent, or adult.
The method of any one of the preceding claims, wherein the individual is at least 10, 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90, 95, or 100 or more years of age.
The method of any one of the preceding claims, wherein the individual has recurrent urinary tract infections.
The method of any one of the preceding claims, wherein the individual is in a medical facility or has been or will be in a medical facility within 1, 2, 3, 4, 5, 6, or 7 days, or within 1, 2, 3, 4 week, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more years.
The method of any one of the preceding claims, wherein the individual lacks a pathogenic E. coli infection.
The method of any one of the preceding claims, wherein the individual has a pathogenic E. coli infection.
The method of any one of the preceding claims, wherein the administering step occurs once.
The method of any one of the preceding claims, wherein the composition comprises an adjuvant.
The method of any one of the preceding claims, wherein the SinH functional fragment is part of a conjugate, wherein the inactive HlyA functional fragment is part of a conjugate, or both.
A composition comprising a non-acylated/inactive form alpha-hemolysin (HlyA) and/or a non-acylated/inactive form or functional fragment thereof in a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.